CompaniesCelsius Therapeutics

Celsius Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (2)
View all

Total Trials

2

As Lead Sponsor

1

As Collaborator

1

Total Enrollment

194

By Phase

PHASE1: 1

By Status

COMPLETED: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
Today
NCT04005183
Hover over trial bars to see details

Recent Trials

NCT05901883Lead Sponsor
First-in-human, Single Ascending Dose Study of CEL383 in Healthy Adult Subjects
PHASE1Completed
48 participants
Started: Jun 20, 2023 · Completed: Jan 17, 2024
NCT04005183Collaborator
Renal Cell Carcinoma Microenvironment Discovery Project
N/ACompleted
146 participants
Started: May 6, 2019 · Completed: Jul 20, 2023
Funding History (2)
D/A
Oct 4, 2019
Filing
D
Jul 3, 2018
Filing
Related Companies
Abbvie
acquired
Celsius Therapeutics | Biotech Hunter | Biotech Hunter